Related Experiment Video
Updated: Feb 28, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations
Songchuan Guo1, Merly Contratto1, George Miller1
1Songchuan Guo, Merly Contratto, George Miller, Lawrence Leichman, Jennifer Wu, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States.
Abstract:
Pancreatic cancer is the third leading cause of cancer mortality in both men and women in the United States, with poor response to current standard of care, short progression-free and overall survival. Immunotherapies that target cytotoxic T lymphocyte antigen-4, programmed cell death protein-1, and programmed death-ligand 1 checkpoints have shown remarkable activities in several cancers such as melanoma, renal cell carcinoma, and non-small cell lung cancer due to high numbers of somatic mutations, combined with cytotoxic T-cell responses. However, single checkpoint blockade was ineffective in pancreatic cancer, highlighting the challenges including the poor antigenicity, a dense desmoplastic stroma, and a largely immunosuppressive microenvironment. In this review, we will summarize available clinical results and ongoing efforts of combining immune checkpoint therapies with other treatment modalities such as chemotherapy, radiotherapy, and targeted therapy. These combination therapies hold promise in unleashing the potential of immunotherapy in pancreatic cancer to achieve better and more durable clinical responses by enhancing cytotoxic T-cell responses.
Insights
Pancreatic cancer shows poor response to immunotherapy alone. Combining immunotherapies with chemotherapy, radiotherapy, or targeted therapy may improve outcomes by boosting T-cell responses.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic cancer is a leading cause of cancer mortality with limited treatment options.
- Immunotherapies targeting immune checkpoints (CTLA-4, PD-1, PD-L1) are effective in other cancers but not pancreatic cancer.
- Challenges in pancreatic cancer include poor antigenicity, dense stroma, and an immunosuppressive tumor microenvironment.
Purpose of the Study:
- To review clinical results and ongoing research on combining immune checkpoint inhibitors with other therapies for pancreatic cancer.
- To explore strategies for overcoming the limitations of single-agent immunotherapy in pancreatic cancer.
Main Methods:
- Review of clinical trial data and published literature on pancreatic cancer immunotherapy.
- Analysis of combination strategies involving chemotherapy, radiotherapy, and targeted therapy.
Main Results:
- Single immune checkpoint blockade has shown limited efficacy in pancreatic cancer.
- Combination therapies aim to enhance cytotoxic T-cell responses and overcome the immunosuppressive tumor microenvironment.
Conclusions:
- Combination immunotherapy strategies hold promise for improving clinical responses in pancreatic cancer.
- Further research and clinical trials are needed to optimize these combination approaches for better and more durable patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...